Xenothera formalizes the effectiveness of its treatment against Omicron and calls on the government – RT en français
| Local News | World News
The Xenothera laboratory announced on December 27 that its XAV-19 treatment against Covid was also effective against the Omicron variant. Problem: the drug is still awaiting its marketing authorization.
In a press release published on December 27 and taken up by France Bleu, the Nantes biotechnology company Xenothera announced the first results of the effectiveness of its XAV-19 treatment against Covid-19. This medical treatment is intended for patients with “moderate” Covid-19, in order to avoid the appearance of complications and a potential transfer to intensive care.
While the treatments allowed for patients with early Covid – if they have any risk factors – are monoclonal antibodies, XAV-19 is a polyclonal antibody. The tests seem to show that, unlike monoclonal antibodies which lose effectiveness on the Omicron variant, XAV-19 retains its effectiveness against the new variant.
The president of the laboratory Odile Duvaux, quoted by France Bleu, explains: “We have known since last week that the monoclonal antibodies currently used as treatment lose their therapeutic activity on the Omicron variant. In this context, our results provide a glimmer of hope for combating this new variant. ”
XAV-19 therefore represents a potential solution for patients carrying the Omicron variant treated with monoclonal antibodies that have become ineffective. In its press release, Xenothera stresses that polyclonal antibodies, less sensitive than monoclonal antibodies to mutations or individual variations in their target, are an asset against a virus which has the characteristic of experiencing multiple mutations.
According to France Bleu, around ten anti-Covid polyclonal antibody projects are under development around the world, XAV-19 being “one of the most advanced”.
The president of the laboratory calls on the government
Unfortunately for the laboratory and for people infected with the Omicron variant, Xenothera treatment has still not received authorization from the ANSM (National Medicines Safety Agency) or the HAS (Haute Autorité de Santé) for its placing on the market.
The president of the biotechnology company has therefore decided to openly challenge the public authorities. “Faced with the emergency health context, we are now calling on the government to ensure that our request for authorization of early access for our treatment benefits from the conditions necessary for its completion given the failure of monoclonal antibodies and the spread of of the Omicron variant. As we have been hammering for more than a year, vaccines and treatments are the two arms of the fight against the epidemic. We remain hopeful that the 25,000 doses of XAV-19 already manufactured and ready for use will be able to benefit patients who need them as soon as possible, ”says Odile Duvaux in a message taken up by France Bleu.
Top Stories Usa News Xenothera formalizes the effectiveness of its treatment against Omicron and calls on the government – RT en français